NHS consultant no private work. Equality, liberty and justice, Chair in Clinical Oncology, Christie & University of Manchester, EIC BMJ Oncology. Own views
🎥 @achoud72 invites you to the Global Forum on GU Oncology!
🌟 Join a global faculty for case-based, multidisciplinary discussions in bladder, renal, and prostate cancer
🌟 Translating the latest GU oncology data to practical takeaways for your clinical practice
📅 2-5 December 2026 | 📍 Amsterdam
👉 Register now: https://t.co/LbvgMIQ9XB
@OncoAlert #RENALC26 #BLADDR26 #PROSCA26
#ASCO26
Talk about real-time updates. NEJM paper now online and my predictions and inferences appear true.
Majority of MFS events were by PET not conventional imaging. "Most distant metastases were identified by PSMA PET (53.0% of those in the apalutamide group and 60.7% in the placebo group)"
VERY IMPORTANTLY: "No significant between-group difference was observed in metastasis-free survival assessed with conventional imaging alone (hazard ratio, 0.84; 95% CI, 0.67 to 1.07)"
Not only does MFS cross 1, but the HR also crosses the surrogate threshold effect (0.81).
@urotoday@PCF_select@US_FDA
Liang et al. (2019) screened 3,262 trials, found 57 Phase II -> III pairs, then were SHOCKED that the selected promising Phase IIs had bigger effects than Phase III. Let’s pull it apart for teaching sake 🧵 1/n
👌 Just back from #ESTRO26 .
🙏 Honored to give several presentations and chair multiple sessions during a congress marked by outstanding science, strong educational value, and inspiring discussions with good friends from around the world.
👍 See you in Milan #ESTRO27